Effect of Growth Hormone replacement therapy on cardiovascular risk factors in adult patients with severe growth hormone deficiency: association with IGF-I concentratio

Completed

• Conditions: growth hormone deficiency; 10021112

• Registration Number: NL-OMON39563
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 32

Inclusion Criteria

- Ongoing surveillance at our centre (VUmc, Amsterdam)
- GH treated (at least one year)
- Men and women with an age between 20 and 65 years, both childhood as adult onset GHD
- Stable substitution therapies for other pituitary hormone deficiencies

Exclusion Criteria

- Subjects with a craniopharyngioma as cause of their GHD or pituitary deficiencies
- Contraindications for the use of Growth Hormone treatment
- (Receiving treatment for) malignant disease (in the past)
- Cardiovascular event less than one year prior to inclusion
- Participation in other studies
- Subjects, who in the opinion of the investigator, are unsuitable in any other way to participate in this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The difference in cardiovascular risk factors at baseline and after 24 weeks of<br /><br>GH treatment with different target levels of IGF-I concentration.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secundary we investigate the effect of GH treatment on glucose metabolism,<br /><br>physical performance, and neuropsychological functioning at different levels of<br /><br>IGF-I.</p><br>